James Barnett
Family Medicine · Peoria, ILNPI 1730103722
Payments from drug & device makers
Across 59 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$282
- Pfizer$127
- Novartis$92
- Dexcom, Inc.$86
- Otsuka America Pharmaceutical, Inc.$64
- Neurocrine Biosciences, Inc.$64
- plus $503 from 15 others
What the payments were for
- Food & beverage$1,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $282 |
| Pfizer | 8 | $127 |
| Novartis | 5 | $92 |
| Dexcom, Inc. | 1 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $61 |
| Abbott | 3 | $61 |
| Phadia US Inc. | 3 | $49 |
| Alkermes, Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $48 |
| Gilead | 2 | $39 |
| Bayer | 2 | $36 |
| Novo Nordisk | 2 | $29 |
| Indivior Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$1,217 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 38 | $40,479 |
| RybelsusSemaglutide | 25 | $32,617 |
| OzempicSemaglutide | 30 | $27,926 |
| MounjaroTirzepatide | 26 | $26,814 |
| TrulicityDulaglutide | 19 | $18,928 |
| XareltoRivaroxaban | 14 | $14,056 |
| EliquisApixaban | 17 | $13,452 |
| Bydureon BciseExenatide Microspheres | 13 | $12,945 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $6,190 |
| Potassium Chloride | 91 | $3,617 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,689 |
| Atorvastatin Calcium | 340 | $2,556 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,419 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,055 |
| Losartan Potassium | 141 | $1,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $29 | $60,54355 claims |
| Johnson & JohnsonXarelto | $48 | $14,05614 claims |
| PfizerEliquis | $127 | $13,45217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Peoria
- David TrachtenbargPeoria$304K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.